Eris Lifesciences announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil’s national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America.
A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the Company’s manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.
Established in 2007, Eris is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care.
Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.
Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY 25 revenue of INR 2,894 cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years.
